We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
Allison Betof Warner, MD, PhD
Hussein Tawbi, MD, PhD
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Future Directions: Targeting LAG-3 in Melanoma Treatment
Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review
Cem Akin, MD, PhD
Daniel J. DeAngelo, MD, PhD
Multidisciplinary Approach to Diagnosing and Managing Indolent Systemic Mastocytosis: The Changing Landscape
Matthew J. Hamilton, MD
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
Jeffrey V. Matous, MD
Donna Catamero, NP
Ajai Chari, MD
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
Meghan Mooradian, MD
Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer
Nadia Harbeck, MD, PhD
Egbert Smit, MD
Susana Campos, MD, MPH
Managing Pulmonary and Cardiac Adverse Events Related to ADC Therapy in Breast Cancer
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education